Clinical Trials
13
Active:0
Completed:7
Trial Phases
3 Phases
Phase 2:4
Phase 3:3
Phase 4:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 4
5 (41.7%)Phase 2
4 (33.3%)Phase 3
3 (25.0%)A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
Phase 4
Terminated
- Conditions
- AnemiaChronic Renal Insufficiency
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 8
- Registration Number
- NCT00495365
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Phase 4
Terminated
- Conditions
- ChemotherapyAnemiaCancer
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 25
- Registration Number
- NCT00495378
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Phase 3
Terminated
- Conditions
- AnemiaNeoplasms
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 98
- Registration Number
- NCT00350090
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
Phase 4
Terminated
- Conditions
- AnemiaKidney Diseases
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 13
- Registration Number
- NCT00338468
A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)
Phase 2
Completed
- Conditions
- Hepatitis CAnemia
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 105
- Registration Number
- NCT00328549
- Prev
- 1
- 2
- 3
- Next
News
No news found